Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Pharmaceutical Executive July 1, 2012	Country Report: Thailand Indochina's biggest pharmaceutical market has quickly matured over the past years due to the implementation of heavy cost containment measures meant to make healthcare more accessible to the patient.
Pharmaceutical Executive May 1, 2011 Stan Bernard	Competition 2.0: Brands vs. Generics Innovator and generics companies are colliding as they invade each other's turf.
The Motley Fool June 22, 2006 Stephen D. Simpson	Merck Goes on the Attack Predator becomes prey in this latest twist in the generics game. Given how much the markets hate uncertainty, that could mean that big generic drug companies might go on sale for patient long-term investors.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Pharmaceutical Executive March 1, 2013	Country Report: China China's pharmaceutical industry is making record gains. Four years ago, China was the world's fifth largest market. Now, it has bypassed France and Germany to become the third largest.
Pharmaceutical Executive June 9, 2014 Genenz et al.	Surviving the Price Wars in Emerging Markets: Three Myths and Three Lessons How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.
Pharmaceutical Executive January 1, 2013	Country Report: Singapore Most executives across the pharmaceutical industry agree; Singapore does not represent any question marks in the future. Furthermore, Singapore's location is ideal for reaching markets east, west, north and south, which form the powerhouse that is Asia-Pacific.
The Motley Fool April 25, 2006 Brian Gorman	Pharma Plays With Fire Drugmakers' short-term gain could lead to long-term pain.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
Pharmaceutical Executive September 1, 2013	Country Report: Indonesia Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia's healthcare system has turned "improving quality" into the top priority of the government of Indonesia.
Managed Care September 2007	Income Said To Influence Use of Generics An observational analysis of pharmacy claims collected from 2001 to 2003 finds that where a person lives and the socioeconomic implications of that location have a lot do with his use of generic drugs.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
Managed Care April 2006 Martin Sipkoff	Blues Plan's Bold Move Brings Generics Savings Blue Cross & Blue Shield of North Carolina is waiving its copayments for generic drugs in a unique six-month pilot program.
Pharmaceutical Executive April 1, 2014	Whatever Happened To Faster Reimbursement For Generics In Europe? The plan to accelerate generic pricing and reimbursement has become another tragic European casualty.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
Managed Care December 2007	Insurers Lean Toward Generic Alternatives More insurers are focusing their attention on a second approach to generic drug management -- generic alternatives, which contain different active ingredients, but have comparable efficacy to brand-name drugs in the same class.
Managed Care May 2006 John Carroll	Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior.
Pharmaceutical Executive September 1, 2006 Reznick & Kobak	Legal: Authorized Generics: Still Legal--and Holding Despite the rattle and hum, courts continue to support the practice of authorized generics. The response? Generic manufacturers are changing the way they argue these cases.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool May 9, 2006 Stephen D. Simpson	Will Par Stay in the Fairway? Par Pharmaceutical is relatively unloved; does that mean opportunity or inferiority for investors?
The Motley Fool November 19, 2009 Brian Orelli	Pfizer's Generic Growth, With a Side of Sashimi A move into Japan isn't a bad idea, but it isn't going to save the company either.
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
Managed Care September 2007 Martin Sipkoff	Patent Law Rulings Work in Favor of Generics Thanks to recent Supreme Court rulings, manufacturers of generic drugs are in a good position to continue expansion of their market share.
Managed Care March 2008 John Carroll	Should Plans Pay Physicians To Switch Patients to Generics? The AMA calls it a kickback, but the industry sees it as just good practice to give doctors an incentive to get patients on equivalent generics
The Motley Fool January 30, 2007 Brian Lawler	Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.
Pharmaceutical Executive January 21, 2014 William Looney	For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
HBS Working Knowledge March 13, 2006 Cynthia D. Churchwell	Global Poverty Needs a Global Answer In this interview, Harvard Business School professor emeritus explains why nonprofits aren't the answer to ending poverty and asks that executives look beyond philanthropy to make lasting positive change.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.